Mesothelioma patients who express too much of the protein PD-L1 are less likely to survive the asbestos cancer than those whose cells express less. That is the message from a new Australian study on mesothelioma prognosis, which backs up the findings from a number of previous PD-L1 studies. In a report published in the Asia-Pacific Journal of Clinical Oncology, oncologist Bella Hai Nguyen and colleagues … Continue reading PD-L1 Linked to Shorter Mesothelioma Survival
Immunotherapy is emerging as one of the most promising new treatment approaches for a wide range of cancers, including malignant pleural mesothelioma, the treatment-resistant lung-related cancer caused by asbestos exposure. Every year, more than 2,500 Americans are diagnosed with pleural mesothelioma. Most will die of the illness within 18 months, even with the most advanced chemotherapeutic, radiotherapeutic, and surgical treatments. But immunotherapy, which recruits the … Continue reading Immunotherapy for Mesothelioma: Who Are the Best Candidates?
Scottish researchers say they have come up with a better way to decide which asbestos-exposed people might benefit from mesothelioma screening or even mesothelioma prevention measures. They have developed an assessment tool to gather detailed information from workers about the time, duration, and nature of their asbestos exposure in order to better quantify their mesothelioma risk. “The assessment is based on the tasks carried out … Continue reading New Assessment Identifies People at High Risk for Malignant Mesothelioma
A new way of delivering chemotherapy drugs to the site of a peritoneal mesothelioma tumor has some unique benefits, but can also be risky. The technique, called pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows doctors to “spray” a solution of chemotherapy drugs directly onto peritoneal tumors through small ports in the abdomen. The intention is to uniformly coat the tumor and help keep chemotherapy drugs in … Continue reading New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients
When it comes to coping with the treatment and side effects of a cancer like malignant mesothelioma, looks matter – especially to female patients. That is the message of a new Italian study on the impact of an “aesthetic care” program for hospitalized cancer patients. The objective of the study, published in the journal Frontiers in Psychology, was to evaluate a support program called “Health … Continue reading Mesothelioma Patients May Benefit from ‘Aesthetic Support’
Tests for the presence or absence of the BAP1 tumor-suppressor protein are likely to continue to play a pivotal role in the diagnosis of malignant mesothelioma. A new evaluation of worldwide studies including more than 1,800 mesothelioma patients found that people who were missing the BAP1 protein almost always had mesothelioma, while those whose cells were still producing BAP1 were not necessarily in the clear. … Continue reading Diagnosing Mesothelioma with BAP1 Testing: Does it Work?
New research suggests that a combination of lung-sparing surgery, highly targeted radiotherapy, and chemotherapy may bolster survival in people with malignant pleural mesothelioma. Researchers at Memorial Sloan Kettering Cancer Center in New York have just published some promising findings on trimodality mesothelioma treatment with hemithoracic intensity-modulated pleural radiotherapy (IMPRINT). Conventional RT vs IMPRINT The team analyzed the cases of 209 mesothelioma patients who underwent the … Continue reading Tri-Modality Treatment Extends Mesothelioma Survival
Peritoneal mesothelioma patients whose bodies produce too many blood platelets may not be good candidates for the treatment combination known as CRS with HIPEC. Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a process for removing as much peritoneal mesothelioma from the abdomen as possible and killing any cancer cells left behind with a wash of heated medication. It has become the preferred … Continue reading Platelet Count Linked to Peritoneal Mesothelioma Survival After Surgery
A biomarker called soluble mesothelin related peptide (SMRP) may be a more reliable way to diagnose malignant pleural mesothelioma from lung fluid than the protein fibulin-3. That is the finding of Italian researchers who tested the diagnostic performance of the two markers in 120 patients, including 33 mesothelioma patients, in an effort to resolve what they call “conflicting data” on the two methods. SMRP and … Continue reading Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers
New research out of Canada suggests that mesothelioma tumor thickness could be used to help predict mesothelioma survival and select the best treatments. Doctors at the University of Toronto compared the thickness of pleural mesothelioma tumors in 65 patients who had not yet received any treatment with their eventual outcomes and found a definite correlation. Summarizing their research in The European Respiratory Journal, the team … Continue reading Mesothelioma Tumor Thickness May Help Predict Treatment Outcomes